FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

35 No-Longer-Marketed NDAs Withdrawn

Federal Register notice: FDA withdraws 35 no-longer-marketed NDAs from multiple applicants.

latest-news-card-1
Federal Register

Meeting on Reauthorizing OTC Drug User Fees

Federal Register notice: FDA announces a public meeting to discuss proposed recommendations for the reauthorization of the Over-the-Counter Monograph ...

latest-news-card-1
Human Drugs

Green Pharma Warned Over CGMP Issues

FDA warns South Koreas Green Pharmaceutical Co. in Jincheon about CGMP violations in its manufacturing of over-the-counter drugs.

latest-news-card-1
Human Drugs

Interoperable Info Exchange Guidance

FDA publishes an updated guidance on standards for the interoperable exchange of information for tracing certain drugs under the Drug Supply Chain Sec...

Medical Devices

Emergency Preparedness Supply Chain

FDA posts recommendations for healthcare providers, medical device manufacturers, and distributors on best practices in preparing for natural disaster...

latest-news-card-1
Medical Devices

Robot Authorized to Disinfect Medical Surfaces

FDA grants Xenex Disinfection Services a de novo marketing authorization for the companys LightStrike+ device, a broad-spectrum ultraviolet light robo...

latest-news-card-1
Human Drugs

Urgent Action on Puberty Blockers Sought

Individuals and organizations opposed to using puberty blockers in gender identity treatment for minors ask FDA to take several steps to increase know...

latest-news-card-1
Human Drugs

FDA Informed Consent Final Guidance

Six Epstein Becker Green attorneys analyze an FDA final guidance on informed consent that leaves the door open to future changes as part of harmonizat...

Human Drugs

X4 Pharm NDA for WHIM Syndrome

X4 Pharmaceuticals files an NDA for a once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (warts, hypogammaglobulinemia, inf...

latest-news-card-1
Human Drugs

Primary Endpoint Met in Alecensa Study: Roche

Roche says recent data from its Phase 3 ALINA study evaluating Alecensa (alectinib) compared with platinum-based chemotherapy met its primary endpoint...